Related Experiment Videos
[Monoclonal antibody therapy for allergic asthma]
Masanori Nishikawa1, Takeshi Matsuse
1Department of Respiratory Medicine, Fujisawa City Hospital.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|March 22, 2002
Summary
The first selective anti-IgE therapy, recombinant humanized monoclonal anti-IgE antibody (rhuMAb-E25), effectively reduces IgE in allergic asthma patients. This treatment improves symptoms and decreases medication use, validating anti-IgE therapy for allergic respiratory conditions.
Area of Science:
- Immunology
- Allergology
Context:
- Allergic respiratory responses are primarily driven by immunoglobulin E (IgE)-mediated pathways.
- Mast cells and basophils play a central role in allergic reactions through IgE binding to Fc epsilon RI receptors.
Purpose:
- To evaluate the efficacy of the first selective anti-IgE therapy, recombinant humanized monoclonal anti-IgE antibody (rhuMAb-E25), in managing allergic asthma.
- To assess the impact of rhuMAb-E25 on IgE levels, Fc epsilon RI receptor density, and clinical outcomes in patients with allergic asthma.
Summary:
- rhuMAb-E25 targets the IgE binding site on Fc epsilon RI receptors, reducing free IgE and receptor density on immune cells.
- Clinical studies demonstrate that rhuMAb-E25 significantly reduces allergic responses, improves asthma symptoms, and decreases the need for rescue medications and corticosteroids.
Impact:
- The effectiveness of rhuMAb-E25 confirms the critical role of IgE in allergic reactions.
- This study supports anti-IgE therapy as a viable and effective immunologic intervention for allergic asthma, offering a new therapeutic avenue.